Inside each of us is our own internal timing device, but the inner-workings of this so-called “circadian clock” are complex, and the molecular processes behind it have long eluded scientists. But now, researchers at the Gladstone Institutes have discovered how one important protein falls under direct instructions from the body’s circadian clock. Furthermore, they uncover how this protein regulates fundamental circadian processes—and how disrupting its normal function can throw this critical system out of sync.
Scientists at the Gladstone Institutes have deciphered how a protein called Arc regulates the activity of neurons—providing much-needed clues into the brain’s ability to form long-lasting memories.
Lennart Mucke, MD, who directs neurological research at the Gladstone Institutes, today received the MetLife Foundation’s 2013 Award for Medical Research in Alzheimer’s Disease at a scientific briefing and awards ceremony in New York.
Shinya Yamanaka next month will receive the Essey Award for his “Commitment to a Cure” from The ALS Association Golden West Chapter. This annual award represents the exceptional determination, spirit and dedication to the fight against amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
Gladstone scientists have discovered that a certain type of DNA damage long thought to be particularly detrimental to brain cells can actually be part of a regular, non-harmful process. The team further found that disruptions to this process occur in mouse models of Alzheimer’s disease—and identified two therapeutic strategies that reduce these disruptions.
Scientists at the Gladstone Institutes have identified a novel mechanism by which a type of low-carb, low-calorie diet—called a “ketogenic diet”—could delay the effects of aging.
Scientists at the Gladstone Institutes have defined for the first time a key underlying process implicated in multiple sclerosis.
Scientists at the Gladstone Institutes and the Stanford University School of Medicine have discovered how modifying a gene halts the toxic buildup of a protein found in nerve cells. These findings point to a potential new tactic for treating a variety of neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease)—a fatal disease for which there is no cure.